1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals Inc.

AQS.V
Aequus Pharmaceuticals Inc.CA flagToronto Stock Exchange Ventures
0.01
CAD
- -
- -
663,172.00Market Cap
Aequus Pharmaceuticals Inc.
AQS.V
(Toronto Stock Exchange Ventures)

Recent

price

0.01

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
- -
- -
- -
0.01
0.02
0.02
0.02
0.03
0.02
0.01
- -
- -
0.01
Revenue per Share
-0.08
-0.1
-0.15
-0.1
-0.06
-0.04
-0.04
-0.01
-0.01
-0.02
-0.02
-0.02
- -
Basic EPS, GAAP
-0.04
-0.05
-0.12
-0.1
-0.06
-0.03
-0.02
-0.01
-0.01
-0.01
-0.02
-0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.08
-0.16
-0.26
-0.29
-0.01
-0.02
-0.06
-0.04
-0.02
-0.04
-0.07
-0.08
-0.09
Book Value per Share
0.01
0.12
0.02
- -
0.02
0.01
-0.01
0.01
0.01
-0.01
-0.03
-0.05
-0.05
Tangible Book Value per Share
21
25
34
47
68
76
80
93
129
133
133
133
133
Basic Weighted Avg Shares
- -
- -
- -
1
1
1
2
3
3
1
- -
1
1
Sales/Revenue/Turnover
- -
- -
- -
-693.18
-343.38
-199.12
-135.86
-20.29
-50.37
-181.05
-1,106.45
-364.1
-62.5
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-2
-2
-5
-5
-4
-3
-3
-1
-2
-3
-3
-2
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-685.84
-340.74
-198.81
-190.26
-40.32
-66.66
-232.65
-1,163.11
-372.74
-71.46
Profit Margin (%)
- -
3
- -
- -
1
1
1
2
1
-1
-4
-7
-7
Working Capital
- -
- -
- -
- -
- -
- -
2
2
- -
1
1
- -
- -
LT Debt
- -
3
1
1
2
2
-1
1
2
-1
-4
-6
-7
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
4.2
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'25
Jun'25
Sep'25
ST Debt
6
6
6
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
133
133
133
Market Capitalization
1
1
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'25
Jun'25
Sep'25
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
7
7
7
Payables & Accruals
1
1
1
ST Debt
6
6
6
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-2.4%
26.12%
50.33%
Free Cash Flow
17.8%
9.94%
-27.81%
Net Income, GAAP
11.75%
9.99%
-26.55%
Sales/Revenue/Turnover
- -
12.41%
129.21%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.01
-0.01
-0.01
- -
-0.02
2024
- -
-0.01
- -
- -
-0.02
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
KYORIN Holdings, Inc. (4569.T)
Cardiol Therapeutics Inc. (CRDL.TO)
Livzon Pharmaceutical Group Inc. (1513.HK)
Ascendis Health Limited (ASC.JO)
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (T14.SI)
Indoco Remedies Limited (INDOCO.NS)
Business
Aequus Pharmaceuticals Inc (TSX-V: AQS) is a Canada-based specialty pharmaceutical company focused on developing and commercializing high-quality, differentiated products targeting neurology, ophthalmology, psychiatry, and transplant therapeutic areas. Founded in 2013 and headquartered in Vancouver, British Columbia, the company commercializes prescription products primarily in the Canadian market through in-licensing, partnerships, and its sales infrastructure; its core offerings include ZIMED PF, a preservative-free bimatoprost 0.03% ophthalmic solution for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, Tacrolimus IR for treating refractory rejection in allogeneic liver, kidney, or heart transplant patients, and Vistitan for glaucoma and ocular hypertension management, alongside promotional services for third-party products and revenue from dry eye treatments. Its development pipeline features REV-0100, a preclinical candidate for Stargardt disease with US FDA Orphan Drug and Rare Pediatric Disease designations, through an exclusive partnership with ReVision Therapeutics granting North American commercial rights negotiation; additional pipeline assets include AQS-1304 for epilepsy and programs enhancing medication adherence via transdermal and extended-release delivery systems in neurology and psychiatry. In recent developments, Aequus announced the sale of ZIMED PF assets to Luvo Medical Technologies in May 2025 for a $400,000 lump-sum payment plus 6% gross profit royalties until 2029, subject to TSX-V approval and expected Q4 2025 closing; the company reported Q2 2025 revenue of $218,220, up 35% year-over-year, driven by ZIMED PF penetration since its 2023 launch, alongside net loss reductions from cost cuts including a Q4 2024 sales team layoff and a July 2025 lease termination for its Vancouver office expiring August 31, 2025; board changes in April 2025 included resignations of Anne Stevens and Chris Clark, with ongoing efforts to pursue strategic partnerships or alternative transactions post-ZIMED divestiture.